MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth

Cancer Research

Volumn 70, Issue 17, 2010, Pages 6880-6890

  Zhang, Yu Wen ^a   Staal, Ben ^a   Essenburg, Curt ^a   Su, Yanli ^a   Kang, Liang ^a   West, Rich ^a   Kaufman, Dafna ^a   DeKoning, Tom ^a   Eagleson, Bryn ^a   Buchanan, Sean G ^b   Vande Woude, George F ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; PROTEIN KINASE INHIBITOR; SCATTER FACTOR; SGX 523; UNCLASSIFIED DRUG; 6-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(1,2,4)TRIAZOLO(4,3-B)PYRIDAZIN-3-YLSULFANYL)QUINOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; PYRIDAZINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SCATTER FACTOR RECEPTOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLON; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; KIDNEY; LUNG; LUNG CARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS; PANCREAS CARCINOMA; PARACRINE SIGNALING; PRIORITY JOURNAL; STOMACH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; C3H MOUSE; CELL CYCLE; CELL GROWTH; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PATHOLOGY; SCID MOUSE;

ANIMALS; CARCINOMA; CELL CYCLE; CELL GROWTH PROCESSES; DRUG SYNERGISM; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, INBRED C3H; MICE, SCID; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDAZINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956296140     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0898     Document Type: Article

References (23)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4: 915-25.
2. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2: 289-300. (Pubitemid 37328782)
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
4. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
5. Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17:77-88.
6. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104:20932-7.
7. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-27. (Pubitemid 44286003)
8. Zhang YW, Graveel C, Shinomiya N, Vande Woude GF. Met decoys: Will cancer take the bait? Cancer Cell 2004;6:5-6.
9. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-14.
10. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16.
11. Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008;18:87-96.
12. Rong S, Bodescot M, Blair D, et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992;12:5152-8.
13. Zhang YW, Su Y, Lanning N, et al. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 2005;24:101-6.
14. Buchanan SG, Hendle J, Lee PS, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther 2009;8:3181-90.
15. Sarkaria JN, Yang L, Grogan PT, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007;6:1167-74.
16. Haines BB, Bettano KA, Chenard M, et al. A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models. Neoplasia 2009;11:39-47.
17. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22:309-25. (Pubitemid 36791889)
18. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66:1721-9.
19. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006;66: 283-9.
20. Gao CF, Xie Q, Zhang YW, et al. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. Mol Cancer Ther 2009;8:2803-10.
21. Merchant M, Zhang Y-W, Su Y, et al. Combination efficacy with Met- MAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors. AACR Meeting Abstracts 2008;2008:1336.
22. Schiller J, Akerley W, Brugger W, et al. Results from ARQ 197-209: a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28, 2010 ASCO Annual Meeting Abstract - LBA7502.
23. Merchant M, Zhang Y, Su Y, et al. MetMAb significantly enhances anti-tumor activity of anti-VEGF and/or erlotinib in several animal tumor models. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2008. Meeting Abstract #556.